AstraZeneca PLC and fellow UK partner Avillion LLP's bid to expand the market for Airsupra has been boosted by "overwhelming" data from a study halted early after the their first-in-class asthma rescue inhaler outperformed the decades-old standard of care.
The firms have presented positive top-level results from the BATURA Phase IIIb trial which showed that Airsupra, a fixed-dose combination of albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS), achieved a statistically significant reduction in the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?